HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Negative 53.9%

Neg 53.9% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $12 to $10.